Search results for "lymphoma"

South Korea’s First Homegrown CAR-T, Rimqarto, Moves Closer to Coverage with 67% Complete Response Rate

South Korea’s First Homegrown CAR-T, Rimqarto, Moves Closer to Coverage with 67% Complete Response Rate

Curocell announced on Sept. 4 that its chimeric antigen receptor T-cell (CAR-T) therapy Rimqarto (generic name: anbalcabtagene autoleucel) was deemed...
Mapping Cancer’s Footprint: Specialized PET/CT Scans Pinpoint Metastasis and Recurrence

Mapping Cancer’s Footprint: Specialized PET/CT Scans Pinpoint Metastasis and Recurrence

Following a cancer diagnosis, patients and their families almost invariably ask the same urgent question: “How far has the cancer spread.
From Bludgeon to Scalpel: ASCO 2026 Signals Oncology’s Shift From ‘Strong Chemo’ to ‘Right Chemo’

From Bludgeon to Scalpel: ASCO 2026 Signals Oncology’s Shift From ‘Strong Chemo’ to ‘Right Chemo’

The standard of care in cancer treatment is undergoing a rapid paradigm shift. For decades, the default oncological...
Curocell’s Homegrown CAR-T Therapy Rimqarto Lands Spotlight in Top Hematology Journal Blood

Curocell’s Homegrown CAR-T Therapy Rimqarto Lands Spotlight in Top Hematology Journal Blood

Curocell, a South Korean clinical-stage biotech company specializing in chimeric antigen receptor T-cell (CAR-T)...
Will Curocell’s First CAR-T Blood Cancer Drug Secure Approval Next Month?

Will Curocell’s First CAR-T Blood Cancer Drug Secure Approval Next Month?

A final decision on the approval of RIMQARTO (anbalcabtagene autoleucel), a chimeric antigen receptor T-cell (CAR-T)...
Warning Signs in the Blood: What Abnormal Bleeding Reveals About Your Cancer Risk

Warning Signs in the Blood: What Abnormal Bleeding Reveals About Your Cancer Risk

When unexpected bleeding occurs, the location and nature of the symptom provide critical clues for a potential...